Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangganling
- Development stage
- Unknown
- Lead developer
- Yunnan Yongzitang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kangganling (抗感灵片) is an approved traditional Chinese medicine (TCM) developed and manufactured by Yunnan Yongzitang, a subsidiary of Hunan Hansen Pharmaceutical. It is formulated as an oral tablet. As a traditional herbal preparation, its therapeutic effects are based on traditional Chinese medical principles rather than defined molecular targets or a specific biological mechanism of action. The name 'Kangganling' translates to 'anti-cold/infection,' indicating its primary clinical use for the relief of symptoms associated with the common cold and influenza.
- Brand names
- Kangganling
- Other names
- Kangganling Pian抗感灵片
Beyond the preview
Go deeper on Kangganling.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangganling.